Compagnie Lombard Odier SCmA’s Repros Therapeutics Inc. RPRX Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-6,000	Closed	-$8K	–	921
2016 Q4	$8K	Hold	6,000	–	–	﹤0.01%	763
2016 Q3	$13K	Hold	6,000	–	–	﹤0.01%	828
2016 Q2	$10K	Hold	6,000	–	–	﹤0.01%	835
2016 Q1	$6K	Hold	6,000	–	–	﹤0.01%	920
2015 Q4	$7K	Hold	6,000	–	–	﹤0.01%	883
2015 Q3	$45K	Hold	6,000	–	–	﹤0.01%	625
2015 Q2	$43K	Hold	6,000	–	–	﹤0.01%	655
2015 Q1	$52K	Buy	+6,000	New	+$53.7K	﹤0.01%	781

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

AIA

Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Compagnie Lombard Odier SCmA's RPRX Position: Q1 2017 in Review

Compagnie Lombard Odier SCmA sold out of Repros Therapeutics Inc. (RPRX) in Q1 2017, closing a stake of 6,000 shares — an estimated $8K sold.

Compagnie Lombard Odier SCmA first reported a position in RPRX in Q1 2015 and held it in 8 quarters. The position peaked at $52K in Q1 2015. 33 funds tracked by Wall St. Rank hold RPRX as of Q1 2017.

Compagnie Lombard Odier SCmA reported no remaining Repros Therapeutics Inc. position as of Q1 2017 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 6,000 Repros Therapeutics Inc. shares in Q1 2017, an estimated $8K.
Compagnie Lombard Odier SCmA first reported a position in Repros Therapeutics Inc. in Q1 2015 and held it in 8 quarters.
Compagnie Lombard Odier SCmA's Repros Therapeutics Inc. position peaked at $52K in Q1 2015.
33 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2017.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2017, filed 15 May 2017.